Theratechnologies Inc. (THTX)
USD 2.7
(-1.1%)
USD 2.7
(-1.1%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 62.12 Million USD | 15.53% |
| 2022 | 53.77 Million USD | 15.5% |
| 2021 | 46.56 Million USD | 18.93% |
| 2020 | 39.15 Million USD | 5.41% |
| 2019 | 37.14 Million USD | 26.43% |
| 2018 | 29.37 Million USD | 82.77% |
| 2017 | 16.07 Million USD | -7.99% |
| 2016 | 17.46 Million USD | 10.2% |
| 2015 | 15.85 Million USD | 1449.74% |
| 2014 | -1.17 Million USD | 64.76% |
| 2013 | -3.33 Million USD | -252.53% |
| 2012 | 2.18 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 17.1 Million USD | 65.38% |
| 2024 Q1 | 10.34 Million USD | -43.75% |
| 2024 Q3 | 18.07 Million USD | 5.7% |
| 2023 Q1 | 15.21 Million USD | -1.91% |
| 2023 Q4 | 18.38 Million USD | 15.72% |
| 2023 Q2 | 12.64 Million USD | -16.92% |
| 2023 FY | 62.12 Million USD | 15.53% |
| 2023 Q3 | 15.88 Million USD | 25.7% |
| 2022 Q4 | 15.51 Million USD | -0.05% |
| 2022 Q2 | 11.5 Million USD | -15.86% |
| 2022 FY | 53.77 Million USD | 15.5% |
| 2022 Q1 | 13.67 Million USD | 0.86% |
| 2022 Q3 | 15.51 Million USD | 34.84% |
| 2021 Q1 | 11.24 Million USD | -17.91% |
| 2021 Q3 | 13.56 Million USD | 3.79% |
| 2021 FY | 46.56 Million USD | 18.93% |
| 2021 Q2 | 13.07 Million USD | 16.31% |
| 2021 Q4 | 13.56 Million USD | -0.04% |
| 2020 Q3 | 9.15 Million USD | -16.76% |
| 2020 FY | 39.15 Million USD | 5.41% |
| 2020 Q1 | 10.17 Million USD | -4.26% |
| 2020 Q2 | 11 Million USD | 8.09% |
| 2020 Q4 | 13.69 Million USD | 49.52% |
| 2019 Q2 | 10.24 Million USD | 32.62% |
| 2019 Q4 | 10.63 Million USD | -2.41% |
| 2019 FY | 37.14 Million USD | 26.43% |
| 2019 Q1 | 7.72 Million USD | -7.93% |
| 2019 Q3 | 10.89 Million USD | 6.34% |
| 2018 Q3 | 7.97 Million USD | 44.25% |
| 2018 Q2 | 5.53 Million USD | 22.75% |
| 2018 Q1 | 4.5 Million USD | -2.79% |
| 2018 FY | 29.37 Million USD | 82.77% |
| 2018 Q4 | 8.39 Million USD | 5.18% |
| 2017 Q4 | 4.63 Million USD | 5.8% |
| 2017 Q2 | 3.19 Million USD | -14.43% |
| 2017 Q1 | 3.73 Million USD | -30.66% |
| 2017 FY | 16.07 Million USD | -7.99% |
| 2017 Q3 | 4.38 Million USD | 36.93% |
| 2016 Q3 | 4.18 Million USD | 4.74% |
| 2016 Q2 | 3.99 Million USD | -1.46% |
| 2016 Q4 | 5.39 Million USD | 28.76% |
| 2016 Q1 | 4.05 Million USD | -21.9% |
| 2016 FY | 17.46 Million USD | 10.2% |
| 2015 FY | 15.85 Million USD | 1449.74% |
| 2015 Q4 | 5.19 Million USD | 7.32% |
| 2015 Q1 | 2.24 Million USD | 186.32% |
| 2015 Q3 | 4.84 Million USD | 21.65% |
| 2015 Q2 | 3.97 Million USD | 77.18% |
| 2014 Q1 | -1.12 Million USD | 18.02% |
| 2014 Q2 | 237.59 Thousand USD | 121.08% |
| 2014 Q3 | -1.14 Million USD | -582.25% |
| 2014 Q4 | 784.35 Thousand USD | 168.45% |
| 2014 FY | -1.17 Million USD | 64.76% |
| 2013 Q3 | -1.16 Million USD | -128.59% |
| 2013 Q2 | -507.58 Thousand USD | -61.1% |
| 2013 FY | -3.33 Million USD | -252.53% |
| 2013 Q1 | -315.08 Thousand USD | -145.89% |
| 2013 Q4 | -1.37 Million USD | -18.48% |
| 2012 Q1 | 1.86 Million USD | -12.77% |
| 2012 Q4 | 686.53 Thousand USD | -67.81% |
| 2012 Q2 | 1.9 Million USD | 2.26% |
| 2012 Q3 | 2.13 Million USD | 11.91% |
| 2012 FY | 2.18 Million USD | 0.0% |
| 2011 Q2 | 942.82 Thousand USD | -0.1% |
| 2011 Q4 | 2.13 Million USD | 35.29% |
| 2011 Q1 | 943.76 Thousand USD | -96.38% |
| 2011 Q3 | 1.57 Million USD | 67.5% |
| 2010 Q3 | 1.5 Million USD | -7.45% |
| 2010 Q2 | 1.62 Million USD | -0.38% |
| 2010 Q1 | 1.63 Million USD | -23.48% |
| 2010 Q4 | 26.05 Million USD | 1629.93% |
| 2009 Q3 | 11.5 Million USD | 630.38% |
| 2009 Q1 | 1.12 Million USD | 411.92% |
| 2009 Q2 | 1.57 Million USD | 39.65% |
| 2009 Q4 | 2.13 Million USD | -81.44% |
| 2008 Q3 | 99.78 Thousand USD | 1884.28% |
| 2008 Q1 | 5101.52 USD | -99.63% |
| 2008 Q2 | 5028.66 USD | -1.43% |
| 2008 Q4 | 220.33 Thousand USD | 120.82% |
| 2007 Q2 | 748.01 Thousand USD | 205.06% |
| 2007 Q3 | 708.13 Thousand USD | -5.33% |
| 2007 Q1 | 245.2 Thousand USD | -13.91% |
| 2007 Q4 | 1.39 Million USD | 96.36% |
| 2006 Q3 | 372.71 Thousand USD | 10159.45% |
| 2006 Q1 | 417.45 Thousand USD | -17.09% |
| 2006 Q2 | 3632.90 USD | -99.13% |
| 2006 Q4 | 284.82 Thousand USD | -23.58% |
| 2005 Q1 | 12.23 Million USD | 1953.06% |
| 2005 Q3 | 344.34 Thousand USD | -31.52% |
| 2005 Q4 | 503.52 Thousand USD | 46.23% |
| 2005 Q2 | 502.84 Thousand USD | -95.89% |
| 2004 Q3 | 445.65 Thousand USD | -22.36% |
| 2004 Q1 | 583.82 Thousand USD | -30.53% |
| 2004 Q2 | 573.98 Thousand USD | -1.69% |
| 2004 Q4 | 596.15 Thousand USD | 33.77% |
| 2003 Q3 | 679.76 Thousand USD | -9.24% |
| 2003 Q4 | 840.38 Thousand USD | 23.63% |
| 2003 Q2 | 748.99 Thousand USD | -2.51% |
| 2003 Q1 | 768.24 Thousand USD | 2.29% |
| 2002 Q4 | 751.02 Thousand USD | -15.25% |
| 2002 Q1 | - USD | -100.0% |
| 2002 Q2 | 939.71 Thousand USD | 0.0% |
| 2002 Q3 | 886.16 Thousand USD | -5.7% |
| 2001 Q1 | 83.95 Thousand USD | 110.89% |
| 2001 Q4 | 2.6 Million USD | 403896.49% |
| 2001 Q3 | 645.30 USD | -96.33% |
| 2001 Q2 | 17.56 Thousand USD | -79.08% |
| 2000 Q1 | 275.66 Thousand USD | 89.04% |
| 2000 Q2 | 200.22 Thousand USD | -27.37% |
| 2000 Q3 | 169.05 Thousand USD | -15.56% |
| 2000 Q4 | 39.8 Thousand USD | -76.45% |
| 1999 Q4 | 145.82 Thousand USD | -45.52% |
| 1999 Q3 | 267.63 Thousand USD | 294.63% |
| 1999 Q1 | 132.58 Thousand USD | -35.15% |
| 1999 Q2 | 67.82 Thousand USD | -48.85% |
| 1998 Q3 | 126.55 Thousand USD | 84.33% |
| 1998 Q4 | 204.45 Thousand USD | 61.56% |
| 1998 Q1 | 70.26 Thousand USD | -48.75% |
| 1998 Q2 | 68.65 Thousand USD | -2.29% |
| 1997 Q1 | 73.06 Thousand USD | 0.0% |
| 1997 Q4 | 137.1 Thousand USD | 90.44% |
| 1997 Q2 | 145.11 Thousand USD | 98.61% |
| 1997 Q3 | 71.99 Thousand USD | -50.39% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -108.823% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 80.952% |
| Journey Medical Corporation | 52.52 Million USD | -18.294% |
| Dynavax Technologies Corporation | 182.11 Million USD | 65.885% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 14.97% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 85.572% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 87.329% |
| PainReform Ltd. | -15 Thousand USD | 414293.333% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1382.379% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -645.026% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -645.026% |
| SCYNEXIS, Inc. | 124.51 Million USD | 50.104% |
| Silver Spike Investment Corp. | 8.1 Million USD | -666.779% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -11115.208% |
| Alpha Teknova, Inc. | 10.29 Million USD | -503.429% |
| Alvotech | -69.42 Million USD | 189.495% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 79.65% |
| Bright Green Corporation | -237.01 Thousand USD | 26312.998% |
| Embecta Corp. | 749.9 Million USD | 91.715% |
| Safety Shot Inc | -74.45 Thousand USD | 83542.792% |
| Procaps Group, S.A. | 239.56 Million USD | 74.066% |
| Cosmos Health Inc. | 4.34 Million USD | -1328.394% |
| Harrow Health, Inc. | 90.55 Million USD | 31.389% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1209.357% |
| Biofrontera Inc. | 16.62 Million USD | -273.663% |
| DURECT Corporation | 6.83 Million USD | -809.515% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 88.137% |
| Cronos Group Inc. | 6.99 Million USD | -788.713% |
| OptiNose, Inc. | 62.35 Million USD | 0.361% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 85.917% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 20604.62% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1934.233% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 79.945% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -1051.706% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -85.538% |
| Radius Health, Inc. | 307.71 Million USD | 79.809% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -516.489% |
| ProPhase Labs, Inc. | 16.23 Million USD | -282.591% |
| Phibro Animal Health Corporation | 312.48 Million USD | 80.118% |
| Procaps Group S.A. | 239.56 Million USD | 74.066% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -4671.813% |
| Viatris Inc. | 6.43 Billion USD | 99.035% |
| Rockwell Medical, Inc. | 8.7 Million USD | -613.798% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -13.819% |
| SIGA Technologies, Inc. | 122.09 Million USD | 49.113% |
| Tilray Brands, Inc. | 223.35 Million USD | 72.183% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -48.456% |
| Shineco, Inc. | 882.16 Thousand USD | -6942.763% |
| PetIQ, Inc. | 252.74 Million USD | 75.418% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 8432.886% |
| Incannex Healthcare Limited | 12 Thousand USD | -517641.667% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 96.637% |
| Alimera Sciences, Inc. | 61.17 Million USD | -1.568% |
| Assertio Holdings, Inc. | 125.04 Million USD | 50.316% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 912286.169% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -847.666% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2677.779% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -129.115% |
| Hempacco Co., Inc. | -1.21 Million USD | 5209.995% |
| Talphera, Inc. | -4.89 Million USD | 1369.234% |
| Alvotech | -69.42 Million USD | 189.495% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 71.973% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 91.244% |
| Currenc Group, Inc. | 17.35 Million USD | -257.962% |
| Kamada Ltd. | 52.59 Million USD | -18.132% |
| Indivior PLC | 907 Million USD | 93.15% |
| Evoke Pharma, Inc. | 4.97 Million USD | -1147.883% |
| Flora Growth Corp. | 17.73 Million USD | -250.259% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2677.779% |
| Evolus, Inc. | 140.52 Million USD | 55.788% |
| HUTCHMED (China) Limited | 453.55 Million USD | 86.302% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 81.938% |
| Akanda Corp. | 111.44 Thousand USD | -55646.575% |